DECN HAILS COMPLETION OF ITS
GENULTIMATE! TBG PANACEA SYSTEM,
3RD PARTY TESTING TO
BEGIN IN NEXT 7 DAYS,
CLINICAL TRIALS TESTING TO BEGIN
IN MAY
++ EQUITY FUND
IN STEALTHY MOVE
TRIED TO GAIN
CONTROL OF DECN
IN MARCH, JUST
AS BIG BOX WAS
IN CONTACT TO BUY
GENULTIMATE TBG WHEN
AVAILABLE, SIGHT UNSEEN
++
LOS ANGELES,
CA -- April 4, 2019 -- InvestorsHub NewsWire
-- Decision
Diagnostics Corp. (OTC
PINK: DECN) Decision Diagnostics Corp. is a 17 year old
diabetes focused bio-technology R&D firm, manufacturer, quality
plan administrator, FDA registered medical device customer support
organization, and exclusive worldwide sales and regulatory process
agent for a growing brand of glucose test strips and meters as
highly accurate alternatives for legacy diabetic, proprietary, and
pet testing glucose test strips.
Decision Diagnostics is
pleased to announce and communicate that the
company's
GenUltimate!
TBG test strip and meter, the next generation panacea at-home
testing product for diabetics, has completed its advanced
development and begun testing for verification
in advance
of third
party testing and patient clinical
trials as
a part of the company's application for 510K
clearance through the U.S. FDA.
Keith Berman,
CEO of DECN commented, "The completion
of GenUltimate!
TBG is the seminal product development event in the company's
history. This product is the answer to our plans and marks a
watershed event in an industry awash with older
technology and
'me-too' products, typically designed in haste, for the singular
purpose of gaining access to the huge and growing U.S. at home
diabetic testing market.
We
view GenUltimate!
TBG as a product where the market has reversed the value
proposition and elected
instead to gain access
to our panacea product under the
pretext of "those guys were able to do it and by-god it
works.""
GenUltimate!
TBG technology is
designed to correct for
Hematocrit (HCT) interference inherent in all at-home
testing methodologies. By accomplishing this correction,
GenUltimate!
TBG offers precision and
accuracy wished for,
but virtually
unheard of in at-home testing of diabetics. In fact, in
several of our recent verification
testing,
GenUltimate!
TBG out-performed even
the reference
methodology. This is quite the accomplishment.
Setting
its own
standard,
GenUltimate!
TBG will be
capable of
reporting glucose results at a reproducible
rate of +/-
8.0%,
in
an industry where +/- 15% is not only the norm but
also
the published
FDA guidance
specifications. The company
plans patent
applications as soon
as a
current round
of financing is accomplished.
The
GenUltimate!
TBG technology will also be used as an enhancement to our
GenUltimate!
and
GenUltimate!
4Pets test strips, now in worldwide commercial use.
Mr. Berman
continued, "As stated
previously we
are putting
all available resources and
energy into our quickly growing product
lines. We now
recognize the value in use of our GenUltimate!
TBG product and technology. To one company
that has already
contacted
us, GenUltimate!
TBG can be viewed as up to a $1.5 billion value add
to
a particular market leader.
And while we
have had discussions with a well branded
big box,
as GenUltimate!
TBG grows closer to commercial availability, we expect
contact with
all of the major
big box companies,
that is if we
choose not to license our panacea product to an august market
leader."
The company's
current portfolio of test strips includes its market
established GenUltimate!,
plus
its GenChoice!,
GenSure!,
and GenUltimate!
TBG test strips, its Avantage!
and
Precise!
Glucometers, and its PetSure!
and
GenUltimate!
4Pets testing products for dogs, cats and horses.
The
company's GenChoice!
test
strips are
part of a current 510K prosecution process with the U.S.
FDA.
ABOUT DECISION
DIAGNOSTICS CORP
Decision Diagnostics Corp. is
the leading manufacturer and worldwide distributor of diabetic test
strips engineered to operate on legacy glucose meters. DECN's
products are designed to operate efficiently and less expensively
on certain glucose meters already in use by almost 7.5 million
diabetics worldwide. With new inspired technology diabetic test
strips already in the final stages of development, DECN products
compete on a worldwide scale with legacy manufacturers currently
selling to 71+ percent of a $12 billion at-home testing
market.
Forward-Looking Statements
This release contains the
company's forward-looking statements which are based on
management's current expectations and assumptions as of
April
3,
2019,
regarding the company's business and performance, its prospects,
current factors, the economy, and other future conditions and
forecasts of future events, circumstances, and results.
CONTACT
INFORMATION:
Decision Diagnostics
Corp.
Keith Berman
(805) 446-2973
info@decisiondiagnostics.com
www.genultimate.com
www.petsureteststrips.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics
Corp.